Results 81 to 90 of about 1,333,671 (322)

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Introduction

CHIMIA, 2008
The presence of hormonally active chemicals ('endocrine disruptors') in the biosphere has become a worldwide environmental concern. In 1999, a report released by the Swiss Federal Office for the Environment (FOEN) concluded that such chemicals ...
Felix R. Althaus
doaj   +1 more source

New approaches for estimating risk from exposure to diethylstilbestrol. [PDF]

, 1999
A subgroup from a National Institute of Environmental Health Sciences, workshop concerned with characterizing the effects of endocrine disruptors on human health at environmental exposure levels considered the question, If diethylstilbestrol (DES) were ...
Cunha, GR, Forsberg, JG, Golden, R, Haney, A, Iguchi, T, Newbold, R, Swan, S, Welshons, W   +7 more
core   +2 more sources

A critical review of the formation of mono- and dicarboxylated metabolic intermediates of alkylphenol polyethoxylates during wastewater treatment and their environmental significance [PDF]

, 2010
This is the author's accepted manuscript. The final published article is available from the link below. Copyright @ 2010 Taylor & Francis.Alkylphenoxyacetic acids, the metabolic biodegradation products of alkylphenol ethoxylates, are commonly found in ...
AEA Technology Environment, Ahel M., Ahel M., Ahel M., APE Research Council, Ashfield L. A., Ball H. A., Barber L. B., Bennie T. D., Bennie T. D., Birkett J. W., Cefic, Cheng C. Y., Comber M. H. I., DiCorcia A., DiCorcia A., DiCorcia A., DiCorcia A., Ding W. H., Ding W. H., Duarte C. L., Dutta A. P., E. Cartmell, Environment Canada and Health Canada, European Commission, European Commission, European Commission, European Commission, Ferguson P. L., Ferguson P. L., Ferguson P. L., Field J. A., Fujii K., Fujita M., Garcia-Reyero N., Gehringer P., Gibson R., Giger W., Giger W., Gray M. A., Gutsche C. D., Haag W. R., Hayashi S., Hill W. J., Hoai P. M., Ike M., Isobe T., Ito Y., J. N. Lester, John D. M., Kinae N., Knepper T. P., Koh Y. K. K., Komori K., Langford K. H., Lee H. B., Lee H. B., Lester J. N., Liu X., M. D. Scrimshaw, Maeda S., Maki H., Maki H., Mann A. H., Mansour M., Manzano M. A., Maruyama K., Mayer T., Minamiyama M., Moraes M. C. F., N. Paterakis, Nguyen M. H., Nimrod A. C., Organisation for Economic Co-operation and Development, Petrovic M., Petrovic M., Petrovic M., Purdom C. E., Reinhard M., Schroder H. F., Servos M. R., Sheahan D., Staples C. A., Stiff M. J., Sumpter J. P., Szymanski A., Szymanski A., T. Y. Chiu, Tanghe T., Tarrant H., Terzic S., Ushida Y., Ventura F., Wagener S., Water Technology International Corporation, Zhang J.   +95 more
core   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Proficiency in performing radiofrequency ablation procedure for non-functioning benign thyroid nodules: a qualitative rather than quantitative matter

Frontiers in Endocrinology
ObjectiveRadiofrequency ablation (RFA) is an emerging non-surgical treatment for benign thyroid nodules (BTN). Despite its proven safety profile, data on the learning curve (LC) required to achieve proficiency are still lacking.Materials and methodsThe ...
Spyridon Chytiris, Marsida Teliti, Marsida Teliti, Laura Croce, Laura Croce, Francesca Coperchini, Beatrice Grillini, Matteo Cerutti, Rodolfo Fonte, Flavia Magri, Flavia Magri, Mario Rotondi, Mario Rotondi   +12 more
doaj   +1 more source

Chemical components of plastics as endocrine disruptors: Overview and commentary

Birth Defects Research, 2020
Bisphenol A and phthalate esters are used as additives in the manufacture of plastic materials, but their ability to leach out with age and heat has resulted in their becoming ubiquitous contaminants of the ecosystem including within human body tissues ...
P. Darbre
semanticscholar   +1 more source

The Science of Endocrine Disruption - Will It Change the Scope of Products Liability Claims? [PDF]

, 2000
The FDA Food Quality Protection Act of 1996 and amendments to the EPA Safe Drinking Water Act require the EPA Administrator, in consultation with the Secretary of Health and Human Services, to develop a screening program for endocrine disrupting effects.
Fassuliotis, Karen
core   +2 more sources

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gabor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Management of alemtuzumab-induced Graves’ disease in pregnancy: a case report and literature review

Frontiers in Immunology
BackgroundAlemtuzumab (ALZ), a monoclonal antibody used to treat relapsing-remitting multiple sclerosis (RRMS), is associated with a high risk of autoimmune thyroid disorders, particularly Graves’ disease (GD).
Marsida Teliti, Marsida Teliti, Maria Gallo, Pietro Costa, Spyridon Chytiris, Flavia Magri, Flavia Magri, Mario Rotondi, Mario Rotondi   +8 more
doaj   +1 more source